Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265% Direct-To-Customer Sales Program Helps Raise Gross Margins To 79% PR Newswire FOSTER CITY, Calif., Feb. 8, 2016 FOSTER...
Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer PR Newswire FOSTER CITY, Calif., Feb. 1, 2016 FOSTER CITY, Calif., Feb. 1, 2016 /PRNewswire/ -- Aoxing Pharmaceutical Company...
Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai PR Newswire JERSEY CITY, N.J., Dec. 10, 2015 JERSEY CITY, N.J., Dec. 10, 2015 /PRNewswire/ -- Aoxing...
Aoxing Pharma Announces Opening Of Government Funded Drug Research Center PR Newswire JERSEY CITY, N.J., Dec. 4, 2015 JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing Pharmaceutical...
Aoxing Pharma Announces Resignation of CFO PR Newswire JERSEY CITY, N.J., Dec. 4, 2015 JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc. PR Newswire NEW YORK, Dec. 3, 2015 NEW YORK, Dec. 3, 2015 /PRNewswire/...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aoxing Pharmaceutical, Inc. - AXN PR Newswire NEW YORK, Dec. 2, 2015 NEW YORK, Dec. 2, 2015 /PRNewswire/...
Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million Direct-To-Customer Sales Program Helps Raise Gross Margin To 80 Percent PR Newswire JERSEY CITY, N.J., Nov. 13, 2015...
Drug Manufacturers - Major Stocks on the Move -- GlaxoSmithKline, Sanofi, Aerie Pharma, TherapeuticsMD, and Aoxing Pharma PR Newswire NEW YORK, July 28, 2015 NEW YORK, July 28, 2015 /PRNewswire/...
Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year PR Newswire JERSEY CITY, N.J., May 15, 2013 JERSEY CITY, N.J., May 15, 2013 /PRNewswire/...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales